NCT07825376

Brief Summary

This randomized controlled trial aims to evaluate the effects of nurse-led branching scenario-based education delivered through virtual reality and tablet on cardiovascular disease risk awareness and adherence to antiplatelet medication in patients with coronary artery disease. Participants will be randomly assigned to a virtual reality education group, a tablet-based education group, or a control group receiving routine hospital education. Cardiovascular disease risk awareness and medication adherence will be assessed before and after the educational intervention and during follow-up.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
54

participants targeted

Target at P25-P50 for not_applicable

Timeline
6mo left

Started Sep 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress16%
Sep 2026Apr 2027

First Submitted

Initial submission to the registry

August 18, 2026

Completed
14 days until next milestone

Study Start

First participant enrolled

September 1, 2026

Completed
16 days until next milestone

First Posted

Study publicly available on registry

September 17, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2027

Last Updated

September 17, 2026

Status Verified

September 1, 2026

Enrollment Period

3 months

First QC Date

August 18, 2026

Last Update Submit

September 11, 2026

Conditions

Keywords

coronary artery diseasevirtual realitytreatment adherence

Outcome Measures

Primary Outcomes (3)

  • cardiovascular disease risk awareness assessment scale score

    Change in cardiovascular disease risk awareness, assessed using the Turkish validated 22-item Cardiovascular Disease Risk Awareness Assessment Scale (CVD-RAAS). The knowledge domain score ranges from 0 to 8, with higher scores indicating higher knowledge about myocardial infarction and stroke. The total score for the 14-item Likert-type awareness subscales ranges from 14 to 56, with higher scores indicating greater awareness of cardiovascular disease risks, healthier dietary intentions, and higher readiness for behavioral change.

    baseline and immediately after the educational intervention

  • medication adherence report scale score

    Change in medication adherence, assessed using the Turkish validated 5-item Medication Adherence Report Scale (MARS-5). Each item is scored on a 5-point Likert scale (1 = always to 5 = never). Total scores range from 5 to 25, with higher scores indicating greater medication adherence.

    Baseline, immediately after the intervention, and 3 months follow-up

  • Cardiovascular Disease Risk Awareness Assessed by the Cardiovascular Disease Risk Awareness Assessment Questionnaire

    Cardiovascular disease risk awareness will be assessed using the Turkish version of the Cardiovascular Disease Risk Awareness Assessment Questionnaire (CDRAAQ), a 22-item instrument consisting of an 8-item knowledge section and three subscales: perceived risk of heart attack/stroke, healthy eating intentions, and perceived benefits and intentions to change. The knowledge items are scored as correct or incorrect, with each correct response receiving 1 point. The subscale items are rated on a 4-point Likert scale from 1 (strongly disagree) to 4 (strongly agree), with reverse scoring applied where appropriate. Higher scores indicate greater cardiovascular disease risk awareness, greater knowledge of heart attack and stroke, and greater readiness for health-related behavioral change.

    Baseline, immediately after the intervention, and 3 months after the intervention.

Study Arms (3)

control group

NO INTERVENTION

participants in the control group receive routine clinical education.

virtual reality education

EXPERIMENTAL

Participants in this arm will receive nurse-led branching scenario-based education on cardiovascular disease risk factors and medication adherence using a virtual reality headset.

Behavioral: Virtual Reality-Based Branching Scenario Education

Tablet Education

EXPERIMENTAL

Participants in this arm will receive nurse-led branching scenario-based education on cardiovascular disease risk factors and medication adherence using a tablet and headphones.

Behavioral: Tablet-Based Branching Scenario Education

Interventions

Participants will first complete a pre-test assessment. They will then receive nurse-led coronary artery disease education through an interactive, branching scenario-based educational program delivered using a virtual reality (VR) headset. The educational content includes visual, interactive, and scenario-based learning activities, with different learning pathways and feedback based on participants' choices. Following the educational intervention, participants will complete a post-test assessment.

virtual reality education

Participants will first complete a pre-test assessment. They will then receive nurse-led coronary artery disease education through an interactive, branching scenario-based educational program delivered using a tablet. The educational content includes visual, interactive, and scenario-based learning activities, with different learning pathways and feedback based on participants' choices. Following the educational intervention, participants will complete a post-test assessment.

Tablet Education

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged 18-65 years.
  • Diagnosed with coronary artery disease.
  • Newly initiated on antiplatelet therapy.
  • Conscious and able to communicate.
  • Physically and cognitively able to use a virtual reality headset.
  • Able to read, write, and understand Turkish.
  • Willing to provide written informed consent.
  • Willing to participate in the education and follow-up process.
  • Has not previously received education about coronary artery disease.
  • Able to use a smartphone.

You may not qualify if:

  • Cognitive impairment or mental illness preventing communication.
  • Visual or hearing impairment preventing participation in the virtual reality education.
  • Participation in another clinical study at the same time.
  • Diagnosis of malignant disease.
  • Bleeding disorder or active bleeding risk.
  • Hospitalization within the previous 3 months due to acute myocardial infarction, stroke, or another serious cardiovascular event.
  • Unable to understand the educational materials.
  • Refusal to provide written informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bolu Abant İzzet Baysal University

Bolu, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Coronary Artery DiseaseTreatment Adherence and Compliance

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesHealth BehaviorBehavior

Central Study Contacts

Saadet Can Çiçek, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

August 18, 2026

First Posted

September 17, 2026

Study Start

September 1, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

April 1, 2027

Last Updated

September 17, 2026

Record last verified: 2026-09

Data Sharing

IPD Sharing
Will not share

for the protection of personal data

Locations